Cytotoxicity of Etlingera pavieana rhizome extract on resistant-cervical cancer cells
Main Article Content
Abstract
Cervical cancer is one of the most common malignancies in women worldwide. Cisplatin-based treatment is most often used in chemotherapy of the disease. However, serious adverse effects and drug-resistant development limit cisplatin in clinical practice. Crude extracts of edible plants can serve as an alternate source of novel anticancer agents that are safe and are able to face chemoresistance. Rhizome of Etlingera pavieana or Raew hawm, an aromatic plant commonly found in Southeast Asia, is a well-known spice and food ingredient used in the Eastern region of Thailand. In the previous studies, E. pavieana rhizome extract exhibited an inhibitory effect on the proliferation of various cancer cells including those resistant to doxorubicin, with much lower toxicity on non-cancer cells. In this ongoing study, the cisplatin-resistant cervical C-33A/R cells were established and were subjected to investigate the cytotoxic effect of the extract. MTT results demonstrated that the viability of C-33A/R cells was significantly reduced after extract treatment in both dose- and time-dependent manners. At 400 µg/mL extract, growth of C-33A/R cells was decreased by 77.32% at 72-hour incubation. The IC50 value against the resistant cells was 269.36 µg/mL which was slightly higher than that of parental cells (230.99 µg/mL). The results suggest E. pavieana rhizome extract as a source of promising anticancer candidates for cervical
cancer treatment.
Article Details
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
References
Cazzaniga, A., Moscheni, C., Trapani, V., Wolf, F. I., Farruggia, G., Sargenti, A., Iotti, S., Maier, J. A., & Castiglioni, S. (2017). The different expression of TRPM7 and MagT1 impacts on the proliferation of colon carcinoma cells sensitive or resistant to doxorubicin. Scientifi c Reports, 7, 40538. https://doi. org/10.1038/ srep40538
Chen, J., Solomides, C., Parekh, H., Simpkins, F., & Simpkins, H. (2015). Cisplatin resistance in human cervical, ovarian and lung cancer cells. Cancer Chemotherapy and Pharmacology, 75(6), 1217-1227. https://doi. org/10.1007/s00280-015-2739-2
Coley, H. M. (2004). Development of drug-resistant models. Methods in Molecular Medicine, 88, 267-273. https://doi.org/10.1385/1-59259- 406-9:267
Davoudi, Z., Akbarzadeh, A., Rahmatiyamchi, M., Movassaghpour, A. A., Alipour, M., Nejati-Koshki, K., Sadeghi, Z., Dariushnejad, H., & Zarghami, N. (2014). Molecular target therapy of AKT and NF-kB signaling pathways and multidrug resistance by specifi c cell penetrating inhibitor peptides in HL-60 cells. Asian Pacifi c journal of Cancer Prevention : APJCP, 15(10), 4353- 4358. https://doi.org/10.7314/ apjcp.2014.15.10.4353
Fang, C. Y., Lou, D. Y., Zhou, L. Q., Wang, J. C., Yang, B., He, Q. J., Wang, J. J., & Weng, Q. J. (2021). Natural products: potential treatments for cisplatin-induced nephrotoxicity. Acta Pharmacologica Sinica, 42(12), 1951-1969. https://doi. org/10.1038/ s41401-021-00620-9
Francisco Fernandez, M., Charfi, C., PilotoFerrer, J., Lidia González, M., Lamy, S., & Annabi, B. (2019). Targeting ovarian cancer cell cytotoxic drug resistance phenotype with Xanthium strumarium L. extract. Evidence-Based Complementary and Alternative Medicine: eCAM, 2019, 6073019. https://doiorg/10.1155/2019/6073019
Haider, T., Pandey, V., Banjare, N., Gupta, P. N., & Soni, V. (2020). Drug resistance in cancer: mechanisms and tackling strategies. Pharmacological Reports : PR, 72(5), 1125-1151. https://doi. org/10.1007/s43440-020-00138-7
Han, T., Zhu, X., Wang, J., Zhao, H., Ma, Q., Zhao, J., & Fan, Q. (2014). Establishment and characterization of a cisplatin-resistant human osteosarcoma cell line. Oncology Reports, 32, 1133-1139. https://doi. org/10.3892/or.2014.3314
Iawsipo, P., & Poonbud, R. (2019). Cytotoxic effect of Etlingera pavieana rhizome extract in Doxorubicin-resistant MDA-MB-231 cells. Proceedings of the 11th National Science Research Conference (pp. 1386-1394).
Iawsipo, P., Srisook, E., Ponglikitmongkol, P., Somwang, T., & Singaed, O. (2018). Cytotoxic effects of Etlingera pavieana rhizome on various cancer cells and identification of a potential anti-tumor component. Journal of Food Biochemistry, 42(4). doi: 10.1111/jfbc.12540
Ikeguchi, M., Hirooka, Y., & Kaibara, N. (2002). Quantitative analysis of apoptosis-related gene expression in hepatocellular carcinoma. Cancer, 95(9), 1938-1945. https://doi.org/ 10.1002/cncr.10898
Krajarng, A., Chulasiri, M., & Watanapokasin, R. (2017). Etlingera elatior extract promotes cell death in B16 melanoma cells via down-regulation of ERK and Akt signaling pathways. BMC complementary and alternative medicine, 17(1), 415. https://doi. org/10.1186/s12906-017-1921-y
Lin, Y. S., Lin, Y. Y., Yang, Y. H., Lin, C. L., Kuan, F. C., Lu, C. N., Chang, G. H., Tsai, M. S., Hsu, C. M., Yeh, R. A., Yang, P. R., Lee, I. Y., Shu, L. H., Cheng, Y. C., Liu, H. T., Lee, K. D., Chang, D. C., & Wu, C. Y. (2018). Antrodia cinnamomea extract inhibits the proliferation of tamoxifen-resistant breast cancer cells through apoptosis and skp2/microRNAs pathway. BMC Complementary and Alternative Medicine, 18(1), 152. https://doi. org/ 10.1186/s12906-018-2204-y
Mbese, Z., Khwaza, V., & Aderibigbe, B. A. (2019). Curcumin and its derivatives as potential therapeutic agents in prostate, colon and breast cancers. Molecules (Basel, Switzerland), 24(23), 4386. https:// doi.org/10.3390/molecules24234386
Naksang, P., Tongchitpakdee, S., Thumanu, K., Oruna-Concha, M. J., Niranjan, K., and Rachtanapun, C. (2020). Assessment of antimicrobial activity, mode of action and volatile compounds of Etlingera pavieana essential oil. Molecules (Basel, Switzerland), 25(14), 3245. https:// doi.org/10.3390/molecules25143245
Pereira, M. M., Haniadka, R., Chacko, P. P., Palatty, P. L., & Baliga, M. S. (2011). Zingiber officinale Roscoe (ginger) as an adjuvant in cancer treatment: a review. Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 16(3), 414-424.
Qi, M., Xie, L., & Duan, G. (2021). Adriamycinresistant cells are significantly less fit than adriamycin-sensitive cells in cervical cancer. Open Life Sciences, 16(1), 53-60. https://doi. org/ 10.1515/biol-2021-0004
Sabli, F., Mohamed, M., Rahmat, A.B., Fadzelly, M., & Bakar, A. (2012). Cytotoxic properties of selected Etlingera spp., & Zingiber spp. (Zingiberaceae) endemic to Borneo. Pertanika Journal of Tropical Agricultural Science, 35, 663-671.
Soumya, T., Lakshmipriya, T., Klika, K. D., Jayasree, P. R., & Manish Kumar, P. R. (2021). Anticancer potential of rhizome extract and a labdane diterpenoid from Curcuma mutabilis plant endemic to Western Ghats of India. Scientific Reports, 11(1), 552. https://doi.org/ 10.1038/ s41598-020-79414-8
Srisook, K., & Srisook, E. (2020). Pharmacological activities and phytochemicals of Etlingera pavieana (Pierre ex Gagnep) R.M.Sm. In Bassam A. R. H. (Ed), Medicinal Plants. IntechOpen. 10.5772/ intechopen.89277
Tuy-On, T., Itharat, A., Maki, P., Thongdeeying, P., Pipatrattanaseree, W., and Ooraikul, B. (2020). In vitro cytotoxic activity against breast, cervical, and ovarian cancer cells and flavonoid content of plant ingredients used in a selected Thai traditional cancer remedy: correlation and hierarchical cluster analysis. Evidence-Based Complementary and Alternative Medicine: eCAM, 2020, 8884529. https://doi.org/10.1155/2020/ 8884529
Wahyuni, W., Diantini, A., Ghozali, M., Subarnas, A., Julaeha, E., Amalia, R., & Sahidin, I. (2021). Cytotoxic and antimigration activity of Etlingera alba (A.D.) Poulsen rhizome. Advances in Pharmacological and Pharmaceutical Sciences, 2021, 6597402. https:// doi.org/ 10.1155/ 2021/6597402
Wu, L., Yang, W., Zhang, S. N., & Lu, J. B. (2015). Alpinetin inhibits lung cancer progression and elevates sensitization drug-resistant lung cancer cells to cis-diammined dichloridoplatium. Drug Design, Development and Therapy, 9, 6119- 6127. https://doi.org/ 10.2147/ DDDT.S92702
Yang J, Wu Y, Wang X, Xu L, Zhao X., & Yang Y. (2017). Chemoresistance is associated with overexpression of HAX-I, inhibition of which resensitizes drug-resistant breast cancer cells to chemotherapy. Tumor Biology, 39, 1-10.
Zhu, H., Luo, H., Zhang, W., Shen, Z., Hu, X., & Zhu, X. (2016). Molecular mechanisms of cisplatin resistance in cervical cancer. Drug Design, Development and Therapy, 10, 1885-1895. https://doi.org/10.2147/ DDDT.S106412